Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent

• Published in: Journal of cardiovascular pharmacology and therapeutics 2004-03, Vol.9 (1_suppl), p.S65-S83
• Main Authors: Antzelevitch, Charles, Belardinelli, Luiz, Wu, Lin, Fraser, Heather, Zygmunt, Andrew C., Burashnikov, Alexander, Di Diego, José M., Fish, Jeffrey M., Cordeiro, Jonathan M., Goodrow, Robert J., Scomik, Fabiana, Perez, Guillermo
• Format: Article
• Language: English
• Subjects: Acetanilides; Action Potentials - drug effects; Angina Pectoris - classification; Angina Pectoris - drug therapy; Angina Pectoris - physiopathology; Animals; Electrophysiologic Techniques, Cardiac - methods; Humans; Ion Channels - classification; Ion Channels - drug effects; Ion Channels - physiology; Long QT Syndrome - chemically induced; Long QT Syndrome - physiopathology; Long QT Syndrome - prevention & control; Piperazines - metabolism; Piperazines - pharmacology; Piperazines - therapeutic use; Ranolazine; Stereoisomerism; Torsades de Pointes - chemically induced; Torsades de Pointes - drug therapy; Torsades de Pointes - physiopathology
• ISSN: 1074-2484; 1940-4034
• DOI: 10.1177/107424840400900106

Ranolazine is a novel antianginal agent capable of producing anti-ischemic effects at plasma concentrations of 2 to 6 μM without a significant reduction of heart rate or blood pressure. This review summarizes the electrophysiologic properties of ranolazine. Ranolazine significantly blocks IKr (IC50 = 12 μM), late INa, late ICa, peak ICa, INa-Ca (IC50 = 5.9, 50, 296, and 91 μM, respectively) and IKs (17% at 30,uM), but causes little or no inhibition of Ito or IKl. In left ventricular tissue and wedge preparations, ranolazine produces a concentration-dependent prolongation of action potential duration (APD) in epicardium, but abbreviation of APD of M cells, leading to either no change or a reduction in transmural dispersion of repolarization (TDR). The result is a modest prolongation of the QT interval. Prolongation of APD and QT by ranolazine is fundamentally different from that of other drugs that block IKr and induce torsade de pointes in that APD prolongation is rate-independent (ie, does not display reverse rate-dependent prolongation of APD) and is not associated with early afterdepolarizations, triggered activity, increased spatial dispersion of repolarization, or polymorphic ventricular tachycardia. Torsade de pointes arrhythmias were not observed spontaneously nor could they be induced with programmed electrical stimulation in the presence of ranolazine at concentrations as high as 100 μM. Indeed, ranolazine was found to possess significant antiarrhythmic activity, acting to suppress the arrhythmogenic effects of other QT-prolonging drugs. Ranolazine produces ion channel effects similar to those observed after chronic exposure to amiodarone (reduced late INa, IKs, IKS, and ICa). Ranolazine's actions to reduce TDR and suppress early afterdepolarization suggest that in addition to its anti-anginal actions, the drug possesses antiarrhythmic activity.